NIH-funded research R21 grant

Using glucose levels to identify early Alzheimer's risk in people with prediabetes.

Official title: Glucose Variability as a Digital Biomarker for Preclinical AD Risk in Prediabetes.

Funded at University of Maryland Baltimore County · NIH-10910153 · Data updated 2026-11-12

This study is looking at how changes in blood sugar levels might help spot early signs of Alzheimer's Disease in older adults who are at risk for Type 2 diabetes, using a special device that tracks glucose levels continuously to see how it relates to thinking and memory.

More Prediabetes research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Maryland Baltimore County
NIH-funded
Lab location1 site (Baltimore, United States)
Project startSeptember 1, 2023
Project endMay 31, 2026
Funding year2024
Award (this year)$224,466
NIH project number5R21AG077647-02
Project IDNIH-10910153 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are older adults aged 21 and above who are at risk for Type 2 diabetes and may be experiencing early cognitive decline.

Less likely to help

Patients who do not have prediabetes or are not at risk for Type 2 diabetes may not benefit from this research.

What this research studies

This research investigates how fluctuations in glucose levels can serve as a digital biomarker for early signs of Alzheimer's Disease (AD) in older adults who are at risk for Type 2 diabetes. By utilizing Continuous Glucose Monitoring (CGM) technology, the study aims to provide a more detailed understanding of how glucose variability affects cognitive function and the risk of developing AD. Participants will have their glucose levels monitored continuously, allowing researchers to identify patterns that may indicate cognitive decline. The goal is to enhance early detection and intervention strategies for those at risk.

Why it matters

Potential benefit: If successful, this research could lead to earlier diagnosis and better management strategies for Alzheimer's Disease in individuals with prediabetes.

How similar studies have gone: While the use of CGM technology is innovative in this context, previous research has shown success in using digital biomarkers for other conditions, suggesting potential for this approach.

Where this research is happening

  • University of Maryland Baltimore County
    Baltimore, United States
    Active

Researchers

  • Principal investigator: Khambaty, Tasneem — University of Maryland Baltimore County
  • Study coordinator: Khambaty, Tasneem

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.